UroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 4,551 Shares

UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 4,551 shares of the company's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now directly owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. This represents a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

UroGen Pharma Price Performance

NASDAQ:URGN traded down $0.23 during trading hours on Friday, reaching $10.72. The stock had a trading volume of 231,947 shares, compared to its average volume of 309,246. The stock has a market capitalization of $251.38 million, a PE ratio of -3.40 and a beta of 1.08. UroGen Pharma Ltd. has a 52 week low of $9.78 and a 52 week high of $20.70. The company has a 50 day moving average price of $11.01 and a two-hundred day moving average price of $12.55. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million for the quarter, compared to analysts' expectations of $24.22 million. During the same period in the previous year, the company earned ($0.68) EPS. As a group, sell-side analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on URGN. HC Wainwright reaffirmed a "buy" rating and set a $60.00 price objective on shares of UroGen Pharma in a research report on Tuesday, October 15th. Oppenheimer reiterated an "outperform" rating and issued a $40.00 price target on shares of UroGen Pharma in a research report on Wednesday, October 16th. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Thursday, January 23rd. Finally, EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a "strong-buy" rating in a report on Monday, October 14th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, UroGen Pharma has an average rating of "Buy" and a consensus price target of $43.70.

Institutional Trading of UroGen Pharma

A number of large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. grew its position in UroGen Pharma by 90.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company's stock worth $103,000 after acquiring an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after purchasing an additional 5,890 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of UroGen Pharma in the 4th quarter worth approximately $126,000. Intech Investment Management LLC bought a new position in shares of UroGen Pharma during the 3rd quarter valued at approximately $155,000. Finally, Verition Fund Management LLC purchased a new stake in UroGen Pharma during the 3rd quarter valued at $168,000. 91.29% of the stock is currently owned by institutional investors.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.